are a leading cause of healthcare-associated infections worldwide. In particular, strains expressing extended-spectrum β-lactamases (ESBLs) and carbapenemases pose serious treatment challenges, leading the World Health Organization (WHO) to designate ESBL and carbapenem-resistant Enterobacteriaceae as 'critical' threats to human health. Research efforts to combat these pathogens can be supported by accessibility to diverse and clinically relevant isolates for testing novel therapeutics.
View Article and Find Full Text PDFBackground: Extra-intestinal pathogenic Escherichia coli (ExPEC) are a leading cause of bloodstream and urinary tract infections worldwide. Over the last two decades, increased rates of antibiotic resistance in E. coli have been reported, further complicating treatment.
View Article and Find Full Text PDFCarbapenem-resistant pose an urgent threat to human health worldwide. sequence type (ST) 14, initially identified in the Middle East and South-Asia and co-harbouring the carbapenemase genes and is now emerging globally. One such strain was detected in the USA in 2013 from a patient initially treated in India that also carried , a 16S rRNA methyltransferase that confers resistance to all clinically relevant aminoglycosides.
View Article and Find Full Text PDFShiga toxin (Stx)-producing (STEC) strain B2F1 produces Stx type 2d, a toxin that becomes more toxic towards Vero cells in the presence of intestinal mucus. STEC that make Stx2d are more pathogenic to streptomycin (Str)-treated mice than most STEC that produce Stx2a or Stx2c. However, purified Stx2d is only 2- or 7-fold more toxic by the intraperitoneal route than Stx2a or Stx2c, respectively.
View Article and Find Full Text PDF